Gülcan Yapici

Publications (2)4.58 Total impact

• Article: CRP and SAP from different species have different membrane ligand specificities.

  Stephan Mattecka, Christopher Bock, Birgit Vogt, Gülcan Yapici, Wieland Schrödl, Christina Janko, Ralf Schindler, Ahmed Sheriff
  [show abstract] [hide abstract]
  ABSTRACT: Human C-reactive protein (CRP) and serum amyloid component P (SAP) are well-characterised ligands for dying and dead cells, while facets of their physiological function still need to be unravelled. We partially characterised CRP and SAP from different species with similar acute-phase systems. Human, rabbit and porcine CRP bound phosphocholine (PC) and phosphoethanolamine (PEt). Human and porcine SAP bound PEt while rabbits seem to have very low levels of SAP or rabbit SAP does not bind PEt. Porcine serum additionally contained other ligands for PC and PEt. Some of them were immunoglobulins. Therefore, rabbits, pigs and humans cover the ability to bind PC and PEt with different extents.
  Autoimmunity 04/2013; · 2.47 Impact Factor
• Article: Specific removal of C-reactive protein by apheresis in a porcine cardiac infarction model.

  Anna Christine Slagman, Christopher Bock, Hassan Abdel-Aty, Birgit Vogt, Frank Gebauer, Gunnar Janelt, Franziska Wohlgemuth, Rene Morgenstern, Gülcan Yapici, Astrid Puppe, [......], Peter Kern, Hans Parsch, Michael Kirschfink, Jeanette Schulz-Menger, Rainer Röttgen, Juliane K Unger, Ulrich Frei, Ralf Schindler, Martin Möckel, Ahmed Sheriff
  [show abstract] [hide abstract]
  ABSTRACT: C-reactive protein (CRP) is a possible causative factor of the destructive processes observed during the weeks after myocardial infarction. We developed a clinically relevant animal model including the removal of CRP from blood plasma utilizing a specific CRP adsorber and the visualization of the infarct scar in the living animal by cardiovascular magnetic resonance imaging as a tool to investigate the impact of CRP after acute myocardial infarction. We describe the facets of this model system and kinetics of clinical blood parameters like CRP and troponin. In addition, we demonstrate the potency of CRP apheresis reducing CRP levels by ~70% in the established treatment system. We showed for the first time that it is possible to conduct apheresis at the following 2 days after acute myocardial infarction in a porcine infarction model and to analyze the infarct by cardiovascular magnetic resonance imaging at day 1 and 14.
  Blood Purification 01/2011; 31(1-3):9-17. · 2.10 Impact Factor